Claims for Patent: 5,747,642
✉ Email this page to a colleague
Summary for Patent: 5,747,642
| Title: | Monomeric insulin analog formulations |
| Abstract: | The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described. |
| Inventor(s): | De Felippis; Michael R. (Indianapolis, IN) |
| Assignee: | Eli Lilly and Company (Indianapolis, IN) |
| Application Number: | 08/458,151 |
| Patent Claims: |
1. Insulin analog-protamine crystals consisting essentially of: human insulin wherein Pro at position B28 is substituted with Lys, Leu, Val or Ala, and Lys at position B29 is Lys or Pro,
des(B28-B30)-human insulin, or des(B27)-human insulin; protamine; zinc; and a phenolic derivative.
2. Crystals of claim 1, which is Lys.sup.B28 Pro.sup.B29 -human insulin, about 0.27 to about 0.32 mg protamine/100 IU of insulin analog, about 0.35 to about 0.9% zinc by weight, and a phenolic derivative. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
